NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results